DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Major indices closed lower on Thursday as market participants digested yet another key inflation reading and new tariff ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Reports Q4 revenue $42.8M, consensus $39.03M. “We achieved significant revenue growth in 2024 driven by strong momentum across our major ...

Edge Capital Group LLC slashed its Merck & Co. stake by 88.8% in Q4, selling 159,265 shares and keeping only 20,073. The firm’s remaining holdings were valued at $1.99 million. Despite this, ...